3 terminated, 2 recruiting, 2 withdrawn, 1 active not recruiting. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 3, Recruiting 2, Withdrawn 2, Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 2, Terminated 2 |
Follow Turning Point Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors TPX-0005, Metformin Hydrochloride, Digoxin - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Withdrawn | Turning Point Therapeutics, Inc. | 2024-11-15 | 2025-04-01 | |
| A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients repotrectinib (TPX-0005) - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Withdrawn | Turning Point Therapeutics, Inc. | 2022-07-28 | 2023-09-26 | |
| Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients Repotrectinib, Osimertinib - Nsclc | Phase 1 | Unknown | Instituto Oncológico Dr Rosell | 32 | 2022-02-11 | 2024-04-03 |
| Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors LM-302 - Advanced Solid Tumor | Phase 1 | Completed | Turning Point Therapeutics, Inc. | 17 | 2021-12-29 | 2024-04-17 |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors TPX-0005, Trametinib - KRAS Mutation-Related Tumors, Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 9 | 2021-09-23 | 2024-04-02 |
| A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC TPX-0131 - Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Turning Point Therapeutics, Inc. | 11 | 2021-07-28 | 2023-05-26 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET elzovantinib (TPX-0022) - Advanced Solid Tumor, Metastatic Solid Tumors | Phase 1 | Active not recruiting | Turning Point Therapeutics, Inc. | 95 | 2019-09-05 | 2025-10-01 |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 500 | 2017-03-07 | 2026-05-27 |
Neoplasm Metastasis (7) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (4) · Adenocarcinoma of Lung (2) · Neoplasms (2) · Sarcoma (2) · Thyroid Neoplasms (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Medullary (1) · Carcinoma, Neuroendocrine (1) · Colonic Diseases (1) · Colonic Neoplasms (1)
repotrectinib (6) · Capsules (1) · Digoxin (1) · Metformin (1) · Rosuvastatin Calcium (1) · Suspensions (1) · TPX-0131 (1) · osimertinib (1) · trametinib (1)
United States (9) · Spain (6) · South Korea (5) · Australia (4) · France (4) · Italy (3) · Canada (2) · Denmark (2) · Singapore (2) · Taiwan (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · China (1) · Germany (1)
PMID 30093503, PMID 32269053, PMID 34814185, PMID 38197815, PMID 40341199, PMID 41639379
2023 (1)